1st Counsel – Lifestyle
Author:
Compass Therapeutics
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
May 5, 2026
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
April 27, 2026
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
April 24, 2026
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
March 5, 2026